{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lane JCE"],"funding":["US National Institutes of Health","NIA NIH HHS","Versus Arthritis","US Department of Veterans Affairs; Janssen Research & Development","Medical Research Council","National Institute for Health Research (NIHR)","NLM NIH HHS","Novo Nordisk Foundation Center for Protein Research","ORD VA","IQVIA","National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)","Wellcome Trust"],"pagination":["3222-3234"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7798671"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["60(7)"],"pubmed_abstract":["Objectives
Concern has been raised in the rheumatology community regarding recent regulatory warnings that HCQ used in the coronavirus disease 2019 pandemic could cause acute psychiatric events. We aimed to study whether there is risk of incident depression, suicidal ideation or psychosis associated with HCQ as used for RA.Methods
We performed a new-user cohort study using claims and electronic medical records from 10 sources and 3 countries (Germany, UK and USA). RA patients ≥18 years of age and initiating HCQ were compared with those initiating SSZ (active comparator) and followed up in the short (30 days) and long term (on treatment). Study outcomes included depression, suicide/suicidal ideation and hospitalization for psychosis. Propensity score stratification and calib"],"journal":["Rheumatology (Oxford, England)"],"pubmed_title":["Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study."],"pmcid":["PMC7798671"],"funding_grant_id":["ACF-2014-13-015","P30 AG059307","R01 LM006910","PI Søren Brunak","T15 LM007079","214588/Z/18/Z","1959917","RES 13-457","21605","2122671"],"pubmed_authors":["Biedermann P","Newby D","Suchard MA","Kolovos S","Zhang L","Rao GA","Rijnbeek P","Wen H","Burn E","Shoaibi A","Xie J","Banda JM","You SC","Wilde M","Morgan-Stewart H","Weaver J","Hester L","Reich C","Lynch KE","Sena AG","Prieto-Alhambra D","Makadia R","Ryan P","Vizcaya D","Alghoul H","Lovestone S","Fister K","Morales DR","Areia C","Woong Park R","Hardin J","Prats-Uribe A","Alser O","Ostropolets A","Nyberg F","Subbian V","Mosseveld M","Lane JCE","Abrahao MTF","Mehta PP","Kaas-Hansen BS","Alshammari TM","Khosla S","Spotnitz M","Duarte-Salles T","Casajust P","Hripcsak G","Kostka K","OHDSI-COVID-19 consortium"],"additional_accession":[]},"is_claimable":false,"name":"Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study.","description":"Objectives
Concern has been raised in the rheumatology community regarding recent regulatory warnings that HCQ used in the coronavirus disease 2019 pandemic could cause acute psychiatric events. We aimed to study whether there is risk of incident depression, suicidal ideation or psychosis associated with HCQ as used for RA.Methods
We performed a new-user cohort study using claims and electronic medical records from 10 sources and 3 countries (Germany, UK and USA). RA patients ≥18 years of age and initiating HCQ were compared with those initiating SSZ (active comparator) and followed up in the short (30 days) and long term (on treatment). Study outcomes included depression, suicide/suicidal ideation and hospitalization for psychosis. Propensity score stratification and calib","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2025-04-18T13:53:51.04Z","creation":"2021-02-21T01:56:42Z"},"accession":"S-EPMC7798671","cross_references":{"pubmed":["33367863"],"doi":["10.1093/rheumatology/keaa771"]}}